IBSRELA generated net sales revenue of $65.0 million; XPHOZAH generated net sales revenue of $25.0 million Company ends Q2 with $238.5 million in cash, cash equivalents and investments Company raises ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...

Eagles All-Pro RB says he is not joining Harrison Butker, Nick Bosa, Tony Romo, and Lawrence Taylor on President Trump's Council on Sports, Fitness, and Nutrition.” ...

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

Employer insurance premiums are expected to rise in 2026, driven by macro-economic factors and increasing prices and use of ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

Washington Post National Health Reporter Paige Winfield Cunningham discusses how the Trump administration is considering ...

Eagles running back Saquon Barkley will join Harrison Butker, Nick Bosa, Tony Romo, and Lawrence Taylor on President Trumps ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.